NCT00141453View on ClinicalTrials.gov

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

577

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

August 31, 2008

Study Completion Date

January 31, 2009

Conditions
Diabetic NephropathyType 2 Diabetes MellitusProteinuria
Interventions
DRUG

olmesartan medoxomil

Tablets 10, 20, or 40 mg

DRUG

Placebo Tablets

Matching placebo tablets

Trial Locations (2)

Unknown

Hong Kong

Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT00141453 - ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial | Biotech Hunter | Biotech Hunter